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1. Introduction 
Advanced stages of uterine cervical cancer, especially those classified as stages IIIa to IVa, 
are unlikely treated with radical surgery alone. Intra-arterial infusion chemotherapy for 
advanced uterine cervical cancer has been shown to result in remarkable clinical outcomes 
because of higher intratumoral concentrations of oncostatics despite minimal adverse effects 
as compared with those administered systemically (Panici et al. 1991, Vermorken 1993, 
Kigawa et al. 1996) Scarabelli and his colleagues (1987) described that the intra-arterial 
infusion as first-line chemotherapy for advanced uterine cervical carcinoma could deliver 
broadened options and improved radicality of the following conventional treatments such 
as surgery or radiotherapy, through the immediate tumor response despite the relative low 
adverse effects. On the contrary, Onishi and his colleagues (Onishi et al. 2000) reported that 
although intraarterial infusion achieved better local response compared to patients treated 
with radiotherapy alone, local recurrence and distant metastasis were inevitable in their 
study group. Studies by Eddy and his colleagues (1995) who used chemotherapy with 
bleomycin, vincristine, mitomycin and cisplatin followed by radiotherapy in patients with 
stage IIIb cervical cancer demonstrated a satisfactory response rate but with intolerable 
toxicity. On the other hand, patients who received intravenous infusion followed by 
radiotherapy had significantly inferior survival compared with those who received 
radiotherapy alone (Tattersall et al. 1995). The reason for such discrepancy in the results 
might be attributed to the insufficient local control of the tumor. 
It is generally accepted that the dose escalation of chemotherapy was linked to improved 
tumor response (Levin and Hryniuk 1987, Levin et al. 1993). Currently, cisplatin has become 
one of the most effective oncostatics in gynecologic oncology and is believed to demonstrate a 
potential antitumor effect against squamous cell carcinoma of the cervix (Thigpen et al. 1981, 
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Ozol and Young 1984). However, higher antitumor effect has been generally accepted to be 
correlated with higher dose intensity but associated with severe toxicity. To reduce the dose-
limiting toxicity and increase the antitumor effect, the authors developed super high-dose 
intra-arterial cisplatin infusion under percutaneous pelvic perfusion with extracorporeal 
chemofiltration (PPPEC) to achieve the ultimate use of cisplatin in the neoadjuvant setting for 
advanced cervical carcinoma (Hamana et al. 2001, Motoyama et al. 2001). The authors have 
shown that PPPEC system achieved a high-dose cisplatin pelvic perfusion with minimal 
adverse effects, permitting cisplatin dose escalation with further augmentation of the tumor 
response. Furthermore, high-dose intra-arterial infusion chemotherapy under PPPEC achieved 
a high frequency of rapid tumor shrinkage of locally advanced uterine cervical cancer with 
favorable performance of the subsequent radical surgery (Motoyama et al. 2004). 
2. Procedures of percutaneous pelvic perfusion with extracorporeal 
chemofiltration  
2.1 Intra-arterial infusion 
Intra-arterial infusion catheters were inserted percutaneously in bilateral internal iliac 
arteries using Seldinger’s techniques via bilateral femoral arteries under fluoroscopic 
guidance. The tip of the catheter was located close to the uterine artery after ceramic-coil 
embolization of both superior and inferior gluteal arteries so as to deliver high 
concentrations of drug in the tumor lesion via the uterine arteries. The other tips of bilateral 
infusion catheters were connected to an infusion pump. 
2.2 Extracoporeal chemofiltration system 
For the first course of PPPEC, the right saphenofemoral junction was exposed through a 
small cut-down incision. Once vascular access established, an activating clotting time 
longer than 200 seconds was maintained with systemic heparinization. After 
anticoagulation, the specially designed inferior vena cava (IVC) occlusion balloon catheter 
(Radiopaque, 60 cm long, 21 French, with a single balloon and three lumens; Sumitomo 
Bake Corporation., Ohtsu, Japan.) (Ku et al. 1995) was introduced through the right 
femoral vein and was advanced under fluoroscopic guidance until the tip was beneath the 
renal vein. The balloon was then inflated with half-strength iodinated contrast at a rate of 
4 ml to 6 ml. To determine whether isolation of the IVC was complete, contrast was 
injected through the drainage lumen under transient occlusion of IVC. Venography taken 
during this injection showed complete retrograde filling of the entire IVC and confirmed 
the absence of contrast leak over the isolation balloon (Figure 1). The distal ends of the 
IVC catheter were connected to the extracorporeal system, including the chemofilter 
cartridge containing active carbon beads (DHP-1; Kuraray Company, Ltd., Osaka, Japan) 
and a centrifugal pump (model BP-80; Biomedicus, Inc., Eden Prairie, MN, U.S.A.), as 
schematically illustrated in Figure 2. 
The IVC blood through the balloon catheter was initially directed to the filter-excluded 
shunt (route A). After hemodynamic stability was verified, the direction of IVC blood flow 
was switched to the chemofiltration route (route B). After the PPPEC system had been 
accomplished, super high-dose cisplatin (140-250 mg/m2) alone or cisplatin plus an ordinal 
dose of pepleomycin (7 mg/m2), mitomycin C (7 mg/m2) and 5-fluorouracil (700 mg/m2) 
were administered during 30 minutes by dose allocation according to the difference in the 
bilateral vascularity of the uterine artery, as verified by the previous arteriogram.  
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A. Complete IVC occlusion by catheter balloon. B. Absence of iodinated contrast leakage above the 
occluding balloon. 
Fig. 1. Roentogenogram and venogram of inferior vena cava (IVC) isolation by catheter 
balloon.  
After PPPEC, the hydration regimen was similar to that of the systemically administered 
cisplatin for the purpose of reducing renal toxicity. The second course of PPPEC was 
performed in the same manner via the left saphenofemoral junction, 2 weeks after the first 
course of PPPEC. 
 
 
Fig. 2. Diagram of percutaneous pelvic perfusion with extracorporeal chemofiltration 
system. Tumor-perfusing blood was drained out in the extracorporeal circuit by a 
centrifugal pump via the drainage channel beneath the balloon in the catheter. After 
chemofiltration, the blood was directed into the IVC circulation again via the return channel 
over the balloon in the catheter. The chemofiltration cartridge (DHP-1) contains active 
carbon beads. 
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3. Clinical examinations 
3.1 Patients 
Twenty-three patients admitted to Kobe University Hospital who had uterine cervical 
cancer stage IIIa to IVa according to the FIGO classification, were included in the present 
review. None of the patients had severe complications, such as diabetes mellitus, 
hypertension, renal failure or any other significant co-morbid conditions, and all had a 
World Health Organization (WHO) performance status (PS) score of 2 or less. All the 
patients had primary, untreated uterine cervical cancer. Prior to the study, patients were 
clinically staged based on pelvic examination, and several laboratory examinations, 
including intravenous pyelography, chest X-ray, cystoscopy, and routine serum chemistries, 
were performed. Metastasis was detected using a computerized tomography (CT) scan, 
whereas the localization and the size of cervical tumors were determined using magnetic 
resonance imaging (MRI) of the abdomen and pelvis. 
During the same period of study, the authors had a total of 609 cervical cancer cases 
managed at our hospital. This includes 109 patients with locally advanced cervical cancer 
classified as stages IIIa, IIIb, or IVa. Among these 109 patients, 23 consented to PPPEC while 
the others received radiotherapy alone (17 patients) or conventional therapy (52 patients) 
consisting of palliative chemotherapy or cytoreductive surgery with or without 
radiotherapy. Radiotherapy was administered as follows: irradiation to the whole pelvis 
was 50.4 Gy, center split at 20 Gy, and vaginal vault at 18 Gy.  
The mean age of the patients was 56.2±12.0 years. The mean diameter of the cervical 
tumor was 4.9±1.8 cm. The PS of all patients was zero. Based on FIGO clinical staging, 1 
patient was classified as having stage IIIa cancer, 17 patients as having stage IIIb cancer, 
and 5 patients as having stage IVa cancer. Histologic types included 21 squamous cell 
carcinoma, 1 adenocarcinoma, and 1 adenosquamous carcinoma. Patients’ characteristics 
are summarized in Table 1. 
 
Age 56.2 ±12.0 y (range: 27-68 y) 
Mean diameter of cervical tumor 4.9 ±1.8 cm (range: 4.5 – 12.0 cm) 
Performance status (based on WHO) 0 
FIGO clinical stage (no. of patients)  
IIIa 1 
IIIb 17 
IVa 5 
Histologic type (no. of patients)  
Squamous cell carcinoma 21 
Adenocarcinoma 1 
Adenosquamous carcinoma 1 
Table 1. Patients’ characteristics 
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Serial blood samples were obtained from prefilter, postfilter, and peripheral blood (radial 
artery) after the start of cisplatin infusion. Tissue samples were obtained by colposcopic 
punch biopsies from cervical lesion after the first course of PPPEC and by radical surgery 2 
weeks after the second course of PPPEC. Plasma and tissue platinum concentrations were 
measured by flameless atomic absorption spectrometry (Pera et al. 1979). 
3.2 Pharmacokinetics of free platinum in extracorporeal chemofiltration circuit 
The time course of mean plasma free-platinum (f-Pt) concentration (n = 3) at each prefilter, 
postfilter, and peripheral site with various cisplatin doses is shown in Figure 3. The peak 
plasma concentration (maximum concentration, Cmax) was noted to be 20 to 30 minutes in 
each time course, but most of them decayed to less than 1.0 µg/ml at 50 minutes after 
initiation of the infusion. This is indicative that although the prefilter mean f-Pt Cmax levels 
increased in a cisplatin dose-dependent manner (range: 7.2—12.2 µg/ml), the postfilter and 
peripheral f-Pt Cmax levels were all in the low range (postfilter range: 2.1—3.6 µg/ml; 
peripheral range: 1.0—3.8 µg/ml). 
 
 
 
 
 
 
140 mg/m2 (open circle with dashed line), 170 mg/m2 (closed circle with dashed line), 200 mg/m2 
(open circle with solid line), 240 mg/m2 (closed circle with solid line). 
Fig. 3. Dynamics of plasma free-platinum concentrations at different sites.  
3.3 Comparison in pharmacokinetics and tumor response between pppec and 
conventional arterial infusion (CAI)  
The pharmacokinetic study comparing peripheral plasma f-Pt concentrations and area 
under the concentration–time curve between PPPEC and conventional arterial infusion 
(CAI) demonstrated that f-Pt Cmax was 2.1 ± 0.1 µg/ml in PPPEC with cisplatin at a dose of 
140 mg/m2. This was only a 33% increase in the Cmax relative to that in CAI (1.5 ± 0.2 µg/ml) 
with cisplatin at a dose of 70 mg/m2, and a 12% increase in the mean area under the 
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concentration–time curve as compared with that in CAI (Figure 4). Conversely, the tumor 
response rate evaluated after completion of two courses of PPPEC was verified to increase 
remarkably from 44% with a 70 mg/m2 cisplatin course to 100% with a 140 mg/m2 cisplatin 
course according to cisplatin dose escalation. 
 
 
 
 
 
 
The arrow shows each Cmax. PPPEC, percutaneous pelvic perfusion with extracorporeal 
chemofiltration; super high-dose intra-arterial cisplatin infusion under percutaneous pelvic perfusion 
with extracorporeal chemofiltration; CAI, conventional arterial infusion. 
 
Fig. 4. Time course of plasma free-platinum concentrations in peripheral circulation.  
3.4 Tissue-platinum concentrations  
The mean tissue Pt concentrations obtained by cervical lesion biopsies at 12 hours and 24 
hours after the first course of PPPEC are shown in Figure 5A. A dose-dependent increase in 
the mean tissue Pt concentration was noted. Particularly, the value (18.6 µg/wet · g) in 
tumor tissue specimens obtained at 24 hours after the first course of PPPEC with cisplatin at 
a dose of 200 mg/m2 cisplatin was remarkably higher compared with that with lower doses 
of cisplatin and with that obtained at 12 hours after PPPEC with the same dose of cisplatin. 
On the other hand, Figure 5B represents the mean tissue Pt concentration in resected 
common iliac lymph nodes and cervical tumor tissues obtained by radical surgery. The 
increase in Pt concentrations in the resected lymph nodes and cervical tumor tissues was 
distinct, depending on cisplatin dose escalation. 
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Fig. 5. Tissue platinum concentrations in cervical tumor lesions and resected lymph nodes. 
Each bar shows the mean tissue Pt concentration in the cervical tumor tissues obtained by 
biopsies at 12 h and 24 h after the first course of PPPEC (a), and in the surgical specimens 
and resected common iliac lymph nodes obtained by radical hysterectomy 2 weeks after the 
second course of PPPEC (b). 
3.5 Adverse effects 
There was little renal impairment, gastrointestinal toxicity, myelosuppression, and alopecia. 
Neither neurogenic nor auditory alteration was detected. The other adverse effects connected 
with PPPEC were mild anemia caused by blood retention in the circuit (~200–300 ml) and 
hemolysis resulting from destruction by resistance in the circuit. All the adverse effects were 
less than grade II (Table 2). There were no critical catheter complications in the present study.  
 
 
Adverse effects No. of patients (%) 
PPPEC related   
 Hemolysis/hematuria 0 
 Thrombocytopenia < 5 X 104/mm3 3 (21.4) 
 Bleeding 0 
Cisplatin related  
 Leukopenia <2,000/mm3 2(14.3) 
 Creatinine >1.5 mg/dl 2(14.3) 
 Nausea/vomiting 3(21.4) 
 Alopecia 0 
Table 2. Adverse Effects Assessment for PPPEC 
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3.6 Clinical response 
In order to evaluate the tumor response, the volumetric reduction of cervical tumors was 
calculated by multiplying three spatial axes based on MRI examination. Tumor response 
was designated as complete response (CR), partial response (PR), minor response (MR) or 
no response (NR), as previously described (Minagawa et al. 1998). On the other hand, tumor 
downstaging and clinical response in the vagina, urinary bladder and parametrium were 
evaluated by colposcopic punch biopsy, cystoscopic examination, drip infusion 
pyelography, MRI, and gynecologic examination. Tumor downstaging or positive tumor 
response was considered when the cancer cells in the lesion disappeared or when there was 
evidence of reduction of parametrial involvement. 
The mean volumetric reduction rate was 76% (range: 50%-100%). The tumor response rate 
evaluated after the second PPPEC were 13% for CR and 74% for PR. The overall tumor 
response (CR + PR) was 87%. Histopathological effects on the surgical specimens revealed 
4% for grade I, 83% for grade II, and 13% for grade III. Tumor downstaging, based on the 
tumor response and the histologic response reached 83% after the second PPPEC (Table 3). 
 
Tumor reduction % (range) 76 % (range: 50.0-100%) 
Tumor response % (no. of patients)  
 CR 13% (3 out of 23 patients) 
 PR 74 % (17 out of 23 patients) 
 MR + NC 13 % 
Histologic effects % (no. of patients)  
 G1 4 % (1 out of 23 patients) 
 G2 83 % (19 out of 23 patients) 
 G3 13 % (3 patients) 
 Overall histologic effects 96 % (22 out of 23 patients) 
Tumor down-staging % (no. of 
patients) 
83 % (19 patients) 
CR, complete response; PR, partial response; MR, minor response; NC, no change 
Table 3. Tumor Response after PPPEC 
3.7 Surgical performance 
Radical surgery was performed on 18 of the 23 patients who had confirmed tumor 
downstaging. The radical surgery performance rate was 78%. The remaining 5 patients, who 
had insufficient stage regression (4 cases) and a poor PS despite tumor downstaging (1 case), 
received radiotherapy. Review of the surgical specimens revealed that 16 of the 18 surgical 
patients had negative surgical margins, leading to a curative surgery rate of 89%.  
Response rate of the involved lesions other than the cervical tumor evaluated after the 
second PPPEC revealed 89% for the parametrium, 94% for the vagina, and 100% for the 
urinary bladder. Lymph node metastasis was detected in 9 of the surgical patients and an 
overall histologic effect in these metastases was 56% (Table 4). 
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Parameter Rate in % (no. of patients) 
Radical surgery 89 % (18 out of 23 patients) 
 Curative surgery 89 % (16 out of 18 patients) 
Radiotherapy 22% (5 out of 23 patients) 
Lesion response  
 Parametrium 89 % (16 out of 18 patients) 
 Vagina 94 % (17 out of 18 patients) 
 Urinary bladder 100 % (5 out of 5 patients) 
Lymph node metastases 50 % (9 out of 18 patients) 
 G3 0 % 
 G2 28 % (5 patients) 
 G1 22 % (4 patients) 
Overall histologic effects 56 % 
Table 4. Evaluation of radical surgery and surgical specimens after PPPEC 
4. Treatment after percutaneous pelvic perfusion with extracorporeal 
chemofiltration (PPPEC) 
Following PPPEC, class III radical hysterectomy based on Rutledge classification was 
performed on patients who demonstrated tumor downstaging according to FIGO 
classification. Radiotherapy was useed in patients uncertain for the tumor downstaging or 
with a poor PS. Adjuvant radiotherapy on the surgical cases was determined based on the 
histopathologic diagnosis of the surgical specimens. Patients who had pelvic, common iliac 
or periaortic lymph node metastasis were subjected to periaortic radiation of 40 Gy aside 
from the whole pelvic and vaginal vault radiation of 18 Gy in patients who had stage IIIa 
cancer after the second course of PPPEC.  
4.1 Clinical outcomes of stage IVa patients 
As shown in Table 5, five patients who had confirmed stage IVa cancer with bladder 
invasion had squamous cell carcinoma. One patient had CR while the other four had PR. All  
 
Case number 1 2 3 4 5 
Tumor size (mm) 32 61 28 63 63 
Tumor response PR PR CR PR PR 
Downstaging Ib Ib <Ib IIb IIIb 
Surgery ＋ ＋ ＋ ＋ － 
Surgical margin － － － － NA 
Lymph node metastases － ＋ ＋ ＋ NA 
Recurrence (months after PPPEC) － － － 11 13 
Current status NED NED NED DOD DOD 
NA, not applicable; NED, no evidence of disease; DOD, died of disease 
Table 5. Characteristics of stage IVa patients and their clinical response after PPPEC 
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the stage IVa patients had tumor downstaging. Four patients underwent a class III radical 
hysterectomy with resultant curative surgery. Three patients had lymph node metastasis 
and two patients had a recurrence. 
4.2 Analysis of recurrent cases 
Recurrence was detected in 10 patients (Table 6). Adjuvant therapy administered to these 
patients consisted of radiotherapy and chemotherapy to those who underwent radical 
surgery, while chemotherapy was delivered to the rest. The initial stages of the 10 cases 
were as follows: 8 stage IIIb cancer and 2 stage IVa cancer. Nine of the 10 patients 
demonstrated lymph node metastasis. The mean time to recurrence was 13.8 months 
(range: 4-32 months). 
 
 
Cases 
Parameters 1 2 3 4 5 6 7 8 9 10 
           
Cell type SCC SCC SCC SCC SCC A SCC SCC SCC SCC 
Surgery ＋ ＋ ＋ ＋ － ＋ ＋ ＋ － － 
S. margins － ＋ ＋ － NA － － － NA NA 
LN mets ＋ － ＋ ＋ ＋ ＋ ＋ ＋ ＋ ＋ 
Adj therapy RCT RCT RCT RCT CT RCT RCT RCT CT CT 
Rec sites l p p p p p ud ud p p 
Rec (months) 16 12 11 8 13 10 11 32 4 11 
A, adenocarcinoma; Adj therapy, adjuvant therapy; CT, chemotherapy; l, lungs; LN mets, lymph node 
metastases; NA, not applicable; p, pelvis; RCT, radiotherapy and chemotherapy; Rec (months), evidence 
of recurrence in months after PPPEC; Rec sites, areas of recurrence; SCC, squamous cell carcinoma; ud, 
undetectable. 
Table 6. Evaluation of recurrent cases 
4.3 Evaluation of survival 
As far as the survival of the patients who received two courses of PPPEC is concerned, the 
5-year progression-free survival was similar among those who underwent radical surgery 
(47%) and those who underwent radiotherapy (50%) after PPPEC. The 5-year progression-
free survival (47%) in the PPPEC group was higher to that of patients who received 
radiotherapy alone (28%) at the authors institution (Kobe University Hospital). 
Furthermore, patients who received PPPEC showed an improvement in the 5-year 
survival rate (74%) compared with that of a similar patient group who received 
radiotherapy alone at our hospital (58%) or those who received conventional therapy, 
which includes those who had palliative chemotherapy or cytoreductive surgery with or 
without radiotherapy (43%) (Figure 6). 
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Fig. 6. Survival rate of patients comparing the different treatments at authors’ institution. 
Patients who received PPPEC showed an improvement of the 5-year survival rate (74%) 
compared with that of similar patient group who received radiotherapy alone (58%) or 
those who received conventional therapy (43%). Survival was compared by the Kaplan-
Meier method.  
5. Discussion 
The use of PPPEC demonstrated a significant increase in tissue Pt-concentrations in patients 
receiving at a dose of 200 mg/m2 cisplatin at a time or more than 400 mg/m2 cisplatin in 
total compared with those receiving cisplatin at a dose of 140 mg/m2 at a time or 280 
mg/m2 cisplatin in total. It might be crucial for tumor cell kill that high intratumoral tissue 
Pt concentrations must be achieved throughout the entire tumor. Providing insight into this 
concept, the dose allocation of cisplatin administered in PPPEC was decided according to 
the vascular disparity among bilateral uterine arteries (Kohno et al. 1993). Because of the 
high reduction rate of f-Pt by DHP-1 filters, the amount of f-Pt passing into the peripheral 
circulation was remarkably decreased; therefore, the dose-limiting toxicities, especially 
nephrotoxicity, were limited and tolerated. 
The mean tissue Pt concentration in common iliac lymph nodes after administration of 
cisplatin at a dose of 400 mg/m2 was 7.4 µg/wet · g, which was higher than the minimal 
concentration (3.4 µg/wet · g) for tumor cell kill (Jaffe et al. 1983), but was lower than the 
satisfactory concentration (17.0 µg/wet · g) for total tumor cell kill. This may be responsible 
for the ineffective control of lymph node metastases. Because tissue Pt concentrations in 
pelvic lymph nodes correlated with the distance from the cervix, it seems that antitumor 
effect in the pelvic lymph nodes, particularly distant lymph nodes, such as common iliac 
and para-aortic nodes, may be inferior to that in cervical tumor lesions.  
In this review, the results of 23 patients with an initial diagnosis of uterine cervical cancer 
stage IIIa to IVa treated with high-dose cisplatin or high-dose cisplatin plus ordinal doses of 
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pepleomycin, mitomycin C and 5-fluorouracil administered in two courses at a 2-week 
interval by means of PPPEC were presented. The reduction of extensive parametrial 
involvement and complete regression of bladder invasion after the second course of PPPEC 
made radical hysterectomy possible in these patients. After the performance of PPPEC, 
radical surgery or radiotherapy were performed. In advanced stages of uterine cervical 
cancer, radical hysterectomy is generally associated with surgical difficulties; hence, the use 
of vessel-sealing system, electrocautery system or argon beam coagulation is advocated. 
Therefore, the prognosis of patients who have stage IIIb or IVa uterine cervical cancer based 
on the present therapeutic strategy with PPPEC was better compared with that of 
conventional therapy. Our findings were congruent to published reports demonstrating that 
the use of intra-arterial infusion was beneficial to patients with advanced uterine cervical 
cancer (Minegawa et al. 1998, Sugiyama et al. 1998, Fujiwaki et al. 1999, Nagata et al. 2000).  
The existence of lymph node metastasis is a poor prognostic factor in patients with cervical 
cancer (Terada et al. 1988, Tinga et al. 1992). Patients with locally advanced uterine cervical 
cancer have a high incidence of lymph node metastasis. In the patients treated with PPPEC, 
the rate of overall histologic effects in metastatic lymph nodes barely reached 56%, a value 
which was less compared with the overall histologic effects in the cervical tumor (96%). This 
could be attributed to the decline in the chemodrug concentrations at areas distant from the 
infusion site. Intra-arterial infusion chemotherapy might have less antitumor effect in the 
pelvic lymph nodes than in the cervical tumor lesions. In order to improve the long-term 
prognosis of locally advanced uterine cervical cancer, it is necessary to increase tumoricidal 
chemodrug concentrations in periaortic lymph nodes, or the pelvic lymph nodes at least 
(Burke et al. 1987). To achieve a satisfactory antitumor effect in periaortic lymph nodes, 
higher doses of cisplatin, an effective combination with other oncostatic agents, or a novel 
drug delivery system will be required (Park et al. 1995, Leone et al. 1996).  
Up to the present time, with 63 months of median follow-up time, the 5- year survival rate 
for patients treated with PPPEC is superior to that of patients who received the conventional 
mode of treatment consisting of palliative surgery or chemotherapy and radiotherapy at the 
authors’ institution (Kobe University Hospital, Kobe, Japan). Furthermore, the 5-year 
progression-free survival and 5-year survival in the PPPEC group are higher than those of 
patients who received radiotherapy alone at authors’ institution. This prompted the authors 
to use the PPPEC system in the management of patients who have locally advanced uterine 
cervical cancer. Although the 5-year progression free survival in those patients who received 
radical surgery or radiation therapy after PPPEC is similar, several clinical and pathological 
factors have been implicated to be of prognostic significance as far as progression-free 
survival and prognosis are concerned. These are as follows: Gynecologic Oncology Group 
PS (0-2), tumor size, tumor growth pattern (exophytic vs. barrel), histologic type, tumor 
grade and age at study entry (Key et al. 2003). Further research should be directed to the 
identification of suitable chemotherapeutic agents, defining clinical indications, and 
development of technical modification to make it more generally applicable. 
6. Conclusion 
The clinical results described in the present review suggest that PPPEC has a therapeutic 
advantage because of prompt tumor downstaging of locally advanced uterine cervical 
cancer with minimal adverse effects, thereby facilitating more options and radicality of the 
subsequent main therapy. This further leads to an improvement of the long-term survival 
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for patients with locally advanced uterine cervical cancer. A prospective randomized trial 
will clarify the optimal mode of initial therapy for patients with stages IIIa - IVa uterine 
cervical cancer. 
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